Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Quest Diagnostics (DGX) PT Raised to $165 at Leerink Partners
October 23, 2024 6:05 AM EDTLeerink Partners analyst Michael Cherny raised the price target on Quest Diagnostics (NYSE: DGX) to $165.00 (from $160.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: DGX was poised for a solid quarter given elevated utilization, even with several moving pieces hitting adjusted EBIT margins. The company delivered solid base business growth, and management continues to... More
